Cancer Stem Cell Compounds for Resistant Tumor Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments fail to effectively target cancer stem cells, leading to the persistence of tumors and high metastatic potential due to the inherent resistance of these cells to conventional cytotoxic agents.
Innovation Solution
Development of compounds represented by Formulae I to XXII, which are designed to inhibit unregulated cell growth, particularly targeting cancer stem cells, and can be administered alone or in combination with other cytotoxic agents to eradicate tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional cytotoxic agents are used to treat cancer, then dividing cancer cells are killed, but cancer stem cells are spared due to inherent resistance
Solution Approach 1:
The patent employs compounds with modified chemical structures (Formulae I to XXII) that change the pharmacological parameters of the treatment, enabling targeting of cancer stem cells while maintaining efficacy against dividing cancer cells. The compounds feature specific molecular modifications including various substituent groups (R1-R22) that alter drug properties to overcome stem cell resistance mechanisms.
2Productivity
If standard chemotherapy is used to treat cancer, then most dividing cancer cells are targeted, but quiescent or slow-dividing cancer stem cells are not affected
Solution Approach 1:
The patent describes compounds that perform multiple functions: they can kill actively dividing cancer cells while also targeting quiescent cancer stem cells. The compounds exhibit broad-spectrum activity against heterogeneous tumor cell populations, including both proliferating and non-proliferating cells, thereby providing universal anti-cancer coverage.
3Reliability
If molecularly-targeted therapies are used to treat cancer, then treatment effectiveness is improved, but cost increases significantly
Solution Approach 1:
The patent presents compounds with simplified chemical structures compared to expensive molecularly-targeted therapies. The compounds are designed to be cost-effective alternatives that can be synthesized more economically while maintaining therapeutic effectiveness against cancer stem cells and heterogeneous tumor populations.
Data Source
AI summary
The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.